- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03805165
Associations of Nighttime Light Exposure During Pregnancy With Neonatal Jaundice:a Multi-centre Prospective Study in China (jaundice)
November 28, 2024 updated by: yang jie, Guangdong Women and Children Hospital
Make a neonatal jaundiced nomogram on Chinese jaundice data by joinning the major neonate centers all around China.
Study Overview
Status
Completed
Conditions
Detailed Description
This was a multi-centre prospective study.
All infants included were born in 8 hospitals in the southern, eastern, northern, western and central regions of mainland China in 2019.
A total of 20839 transcutaneous bilirubin(TCB) measurements were performed with 2977 neonates at designated time points.
The mean NTL exposure during pregnancy was respectively calculated based on each participant's residential address over the study course.
The primary outcome was whether the neonate was diagnosed with hyperbilirubinemia within the first seven days of life.
The effect of maternal nocturnal light exposure on neonate jaundice analyzed with lasso regression and random forest machine learning methods.
Study Type
Observational
Enrollment (Actual)
2977
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 511442
- Jie Yang
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 day to 1 week (Child)
Accepts Healthy Volunteers
Yes
Sampling Method
Probability Sample
Study Population
Term and near term newborns, whos gestational age was more than 35 weeks(≥35)
Description
Inclusion Criteria:
gestational age more than 35 weeks(≥35) -
Exclusion Criteria:
all kinds of congenital diseases, infants with pathologic jaundice
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
neonate
transcutaneous bilirubin(TCB) measurements were performed with 2977 neonates at designated time points.
The mean NTL exposure during pregnancy was respectively calculated based on each participant's residential address over the study course.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hour-specific Transcutaneous Bilirubin Level
Time Frame: 1 year
|
make neonatal jaundiced nomogram base on the hour-specific transcutaneous bilirubin data
|
1 year
|
|
whether the neonate was diagnosed with hyperbilirubinemia within the first seven days of life
Time Frame: 2019
|
whether the neonate was diagnosed with hyperbilirubinemia within the first seven days of life
|
2019
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2019
Primary Completion (Actual)
March 31, 2019
Study Completion (Actual)
December 31, 2019
Study Registration Dates
First Submitted
December 25, 2018
First Submitted That Met QC Criteria
January 14, 2019
First Posted (Actual)
January 15, 2019
Study Record Updates
Last Update Posted (Actual)
December 3, 2024
Last Update Submitted That Met QC Criteria
November 28, 2024
Last Verified
November 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Guangdong WCH
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Jaundice, Neonatal
-
Muhammad ZarkNot yet recruitingPhysiological Neonatal Jaundice | Physiological HyperbilirubinaemiaPakistan
-
Ege UniversityAssociate Professor Figen YARDIMCIRecruitingUnspecified Fetal and Neonatal JaundiceTurkey
-
Hillerod Hospital, DenmarkPicterus ASRecruitingNeonatal Hyperbilirubinemia | Neonatal JaundiceBotswana
-
Guizhou Provincial People's HospitalRecruiting
-
Picterus ASNorwegian University of Science and TechnologyTerminatedNeonatal JaundiceUganda
-
University of MinnesotaHennepin Healthcare Research InstituteCompleted
-
Guangzhou Women and Children's Medical CenterRecruitingNeonatal Hyperbilirubinemia | Neonatal Jaundice | Hemolysis NeonatalChina
-
Kanuni Sultan Suleyman Training and Research HospitalCompletedABO Incompatibility | Neonatal Jaundice From Other Specified Causes | ABO Hemolytic DiseaseTurkey
-
National Liver Institute, EgyptCompleted